- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04844346
Plant Stanol Esters and COVID-19 Vaccination Response
11. februar 2022 oppdatert av: Maastricht University Medical Center
The Effect of Plant Stanol Ester Consumption on the Vaccination Response to a COVID-19 Vaccine
Plant stanols are known to lower low-density lipoprotein cholesterol (LDL-C).
However, studies have suggested that these compounds also beneficially influence the immune system, e.g.
increasing vaccine-specific antibody titers.
BMI has previously been negatively associated to vaccination responses.
If plant stanols indeed have beneficial effect on the immune system, people with overweight or obesity might benefit from consuming plant stanols prior to receiving the COVID-19 vaccination.
The primary objective of this study is to demonstrate clinical benefits of consumption of plant stanols (delivered via products enriched with plant stanol esters) on the vaccination response to a COVID-19 vaccine in overweight or obese patients.
The main study endpoint is vaccination response to a COVID-19 vaccine.
Secondary endpoints include amongst others hematological, inflammatory and immunological parameters (e.g.
hs-CRP, leukocyte differential count) and metabolic markers (e.g.
blood lipid profiles, plasma glucose, serum insulin, HOMA-IR).
Studieoversikt
Status
Avsluttet
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
48
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Limburg
-
Maastricht, Limburg, Nederland, 6229ER
- Maastricht University Medical Center
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Ja
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Men and women
- Aged 18 years or older
- BMI between 27 and 35 kg/m2
- Currently not using products containing plant sterols or stanols (products with a cholesterol lowering claim of Becel ProActiv, Benecol, Danacol, store brands)
- Willing to abstain from products containing plant sterols or stanols during the study (products with a cholesterol lowering claim of Becel ProActiv, Benecol, Danacol, store brands)
- Willing to keep the intake of fish oil and vitamin supplements constant
Exclusion Criteria:
- Already received COVID-19 vaccination
- Already had a positive test for COVID-19 (this includes all types of tests, e.g. PCR tests or antibody tests)
- Allergy to an ingredient of the mini drinks
- Having donated blood within one month prior to the start of the study, or planning to donate blood during the study
- Pregnant women
- Breastfeeding women
- Excessive alcohol use (>20 consumptions per week)
- Regular use of soft or hard drugs
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Plant stanol group
This arm receives 4g of plant stanols per day (delivered as plant stanol esters) by consuming mini drinks (100 mL each).
|
Oat milk based mini drinks (100 mL) containing 2g plant stanols each (delivered as plant stanol esters).
First dose of one of the COVID-19 vaccines.
Participants have to wait until they are invited to receive the vaccine by the government; this study does not interfere with national planning of the vaccines.
|
|
Placebo komparator: Placebo group
This arm receives mini drinks without added plant stanols (delivered as plant stanol esters).
|
First dose of one of the COVID-19 vaccines.
Participants have to wait until they are invited to receive the vaccine by the government; this study does not interfere with national planning of the vaccines.
Oat milk based mini drinks (100 mL) without added plant stanols (delivered as plant stanol esters).
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Vaccine specific antibody titers
Tidsramme: Change T=0 and T= 4 weeks
|
The response to the COVID-19 vaccine will be measured by quantifying specific antibody titers (vaccine specific IgG and IgM).
These titers will be measured in blood samples collected weekly during the month after vaccination by suitable ELISAs.
|
Change T=0 and T= 4 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Immune parameters (1)
Tidsramme: T=-1 (start study), T=0 (day before vaccination), T=4 weeks after vaccination
|
Cytokine production by PBMCs after stimulation with antiCD3-antiCD28 antiCD28 antibodies using the TruCulture system
|
T=-1 (start study), T=0 (day before vaccination), T=4 weeks after vaccination
|
|
Immune parameters (2)
Tidsramme: T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
|
hsCRP
|
T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
|
|
Leukocyte count
Tidsramme: T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
|
Number of leukocytes measured in EDTA plasma
|
T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
|
|
Leukocyte differential count
Tidsramme: T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
|
Number of subgroups of leukocytes measured in EDTA plasma
|
T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
|
|
Fasted metabolism (1)
Tidsramme: T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
|
Serum non-cholesterol sterols and stanols
|
T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
|
|
Fasted metabolism (2)
Tidsramme: T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
|
Serum lipid and lipoprotein profile
|
T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
|
|
Fasted metabolism (3)
Tidsramme: T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
|
Glucose metabolism (including e.g.
plasma glucose, serum insulin and calculated HOMA-IR)
|
T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
|
|
Anthropometry (1)
Tidsramme: T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
|
Body weight
|
T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
|
|
Anthropometry (2)
Tidsramme: T=-1 (start study)
|
Height
|
T=-1 (start study)
|
|
Anthropometry (3)
Tidsramme: T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
|
Waist circumference
|
T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
|
|
Anthropometry (4)
Tidsramme: T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
|
Hip circumference
|
T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
|
|
Anthropometry (5)
Tidsramme: T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
|
Waist-to-hip ratio
|
T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
|
|
Diet
Tidsramme: T=-1 (start study) and T=4 weeks after vaccination (end study)
|
Food frequency questionnaire is used to determine if the participants maintain their habitual diet and to determine if the participants do not consume plant stanols and/or sterols outside the intervention
|
T=-1 (start study) and T=4 weeks after vaccination (end study)
|
|
Diary outcomes (1)
Tidsramme: T=-1 (start study) until T=4 weeks after vaccination (end of study)
|
General illness
|
T=-1 (start study) until T=4 weeks after vaccination (end of study)
|
|
Diary outcomes (2)
Tidsramme: T=0 (day before vaccination) until T=4 weeks after vaccination (end of study)
|
Side effects COVID-19 vaccine
|
T=0 (day before vaccination) until T=4 weeks after vaccination (end of study)
|
|
Diary outcomes (3)
Tidsramme: T=-1 (start study) until T=4 weeks after vaccination (end of study)
|
Medication intake
|
T=-1 (start study) until T=4 weeks after vaccination (end of study)
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Samarbeidspartnere
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
22. april 2021
Primær fullføring (Faktiske)
11. januar 2022
Studiet fullført (Faktiske)
11. januar 2022
Datoer for studieregistrering
Først innsendt
13. april 2021
Først innsendt som oppfylte QC-kriteriene
13. april 2021
Først lagt ut (Faktiske)
14. april 2021
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
2. mars 2022
Siste oppdatering sendt inn som oppfylte QC-kriteriene
11. februar 2022
Sist bekreftet
1. februar 2022
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- METC 21-013
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
produkt produsert i og eksportert fra USA
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .